A5000113976- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- SARS-CoV-2 and COVID-19 Research
- Asthma and respiratory diseases
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Acute Myocardial Infarction Research
- Blood Coagulation and Thrombosis Mechanisms
- Tracheal and airway disorders
- Statistical Methods in Clinical Trials
- Occupational exposure and asthma
- Eosinophilic Esophagitis
- Cardiac Arrhythmias and Treatments
- Respiratory and Cough-Related Research
- Long-Term Effects of COVID-19
- Pneumonia and Respiratory Infections
- COVID-19 Impact on Reproduction
- Health Systems, Economic Evaluations, Quality of Life
- SARS-CoV-2 detection and testing
- Coronary Interventions and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
AstraZeneca (United States)
2022-2025
Beth Israel Deaconess Medical Center
2016-2018
Harvard University
2016-2018
Mount Sinai Medical Center
2016
Icahn School of Medicine at Mount Sinai
2016
University of Freiburg
2016
Bayer (Germany)
2016
Edinburgh Royal Infirmary
2016
University of Edinburgh
2016
Newark Beth Israel Medical Center
2016
Background Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its effectiveness SEA according previous biologic use key baseline characteristics important for treatment selection. Methods XALOC-1 is a large, multinational, retrospective, observational, study programme of benralizumab adults with SEA. This 48-week integrated analysis assessed annualised...
Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that regimen rivaroxaban P2Y12 inhibitor monotherapy or DAPT could reduce bleeding and thereby have favorable impact on all-cause mortality the need for rehospitalization.Stented subjects nonvalvular (n=2124) were randomized 1:1:1 administration reduced-dose 15 mg...
Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis the factor Xa inhibitor betrixaban to reduce risk stroke compared standard-dose enoxaparin in this population was assessed retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).Hospitalized acutely medically ill subjects (n=7513) were randomized double-dummy...
Plain Language SummaryWhat is this summary about?This a of an article originally published in the European Respiratory Journal, which presented combined results from five retrospective real-world studies (i.e., looking at data collected during historical medical appointments) that each took place different country and which, together, formed XALOC-1 study programme. looked how effective benralizumab injections were clinical practice treating type asthma called 'severe eosinophilic...
Background Extended‐duration betrixaban showed a significant reduction in venous thromboembolism the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given variable clinical impact of different efficacy and safety events, one approach to assess net outcomes is include only those events that are either fatal or cause irreversible harm. Methods Results This was post hoc analysis trial—a multicenter, double‐blind, randomized controlled comparing...
Summary Competing risk methods are time‐to‐event analyses that account for fatal and/or nonfatal events may potentially alter or prevent a subject from experiencing the primary endpoint. provide more accurate and less biased estimate of incidence an outcome but rarely applied in cardiology trials. APEX investigated efficacy extended‐duration betrixaban versus standard‐duration enoxaparin to composite symptomatic deep‐vein thrombosis (proximal distal), pulmonary embolism, venous...
Nirsevimab is an extended half-life, highly potent neutralizing monoclonal antibody against the respiratory syncytial virus (RSV) fusion protein, with efficacy in preventing RSV-associated medically attended (MA) lower tract infection (LRTI) infants and vulnerable children (aged ≤24 months). This post-hoc exploratory analysis examined incidence of LRTI from RSV other pathogens during a 2:1 randomized, double-blind, placebo-controlled, phase 3 study nirsevimab, healthy-term late-preterm (i.e....
Background:In hospitalized patients elevated D-dimer concentration is associated with an increased risk of occurrence for VTE and mortality.D-dimer may be used to identify medical at risk, who might benefit from extended thromboprophylaxis following hospitalization acute illness.Methods: This a post hoc sub-study the Acute Medically Ill Prevention Extended Duration Betrixaban (APEX) trial.The aim was evaluate modulation treatment effect betrixaban versus standard duration enoxaparin as...